

# FOR WOMEN SUFFERING CHRONIC HAIR LOSS (CHL)

V. DUROSIER, MD<sup>1</sup> • G. SYLVAIN, MD<sup>2</sup> • M. JHIN, MD<sup>3</sup> • N. KRYWONIS, MD<sup>4</sup> • J. LEDDON, MD<sup>5</sup> L. PARKER, MD<sup>6</sup> • M. GOLDGEIER, MD<sup>7</sup> • K. WITFILL, MD<sup>8</sup> • L. EVANS, MD<sup>9</sup> • D.R. SPEY, MD<sup>10</sup> D. DAY, MD<sup>11</sup> • ANTONELLA TOSTI, MD<sup>12</sup>

DUCRAY LABORATORIES, LAVAUR, France • <sup>2</sup> EAGLE'S LANDING LONGEVITY CENTER, STOCKBRIDGE, GA, USA
<sup>3</sup> PREMIER DERMATOLOGY, SAN FRANCISCO, CA, USA • <sup>4</sup> SKIN CARE COLORADO, DENVER, CO, USA
<sup>5</sup> BOULDER VALLEY CENTER FOR DERMATOLOGY, LAFAYETTE, CO, USA • <sup>6</sup> DERMATOLOGY SPECIALISTS, BENCHWOOD, OH, USA <sup>7</sup> CLINTON CROSSING DERMATOLOGY, ROCHESTER, NY, USA • <sup>8</sup> BAY DERMATOLOGY, PORT RICHEY, FL, USA • <sup>9</sup> DERMATOLOGIST, CHAPPAQUA, NY, USA • <sup>10</sup> ADVANCED DERMATOLOGY AND SKIN CARE, WEST ORANGE, NJ, USA • <sup>11</sup> DAY DERMATOLOGY & AESTHETICS, NEW YORK, NY, USA • <sup>12</sup> UNIVERSITY OF MIAMI HOSPITAL, MIAMI, FL, USA.

## **LEARNING OBJECTIVE**

Present an alternative treatment in management of female chronic hair loss.

## **INTRODUCTION**


25% of women from 35 to 45 years old and 45% of women over 40 are experiencing CHL (1). The aim of this study was to investigate the effect of a specific tetrapeptide-based lotion in female CHL.

#### **METHODOLOGY**

Ten American dermatologists had conducted a study with women suffering from CHL for longer than 1 year. Patients applied 1ml of the lotion once daily for a 3-month period. Global hair loss severity, hair density were evaluated by physicians and patients at baseline (T0) and week 12 with a 10 points scale. Efficacy, clinical response and tolerance of the product were also evaluated.

### **RESULTS**

47 women with an average age of 52 participated in the study. After 3 months of use, dermatologists and patients confirmed a significant improvement in hair density (4,8 to 5,4; p=0, 0192) (Fig 1). At week 12, dermatologists observed a significant decrease in the general severity of chronic alopecia (5,1 to 4,5; p<0,05). The overall efficiency was considered as "good to excellent" for over 81% of subjects. The cutaneous tolerance of the product for 93% of subjects was very good.



## **CONCLUSION**

This study has shown that the tetrapeptide lotion is effective and well tolerated in the management of female CHL.